Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.36 |
| ▸ | BRD7 | Q9NPI1 | 4/20 | 0.36 |
| ▸ | BRD2 | P25440 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279323 | 0.78 | BRD4 (0.37) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL19869613 | 0.77 | BRD4 (0.33) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL16650601 | 0.75 | BRD4 (0.34) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL19478468 | 0.75 | ALDH1A1 (0.40) | BRD4BRD9BRD7BRD2ALDH1A1 | |
| SCHEMBL292139 | 0.75 | — | — | |
| SCHEMBL19493628 | 0.73 | BRD4 (0.38) | BRD4BRD9BRD2LMNAPOLB | |
| SCHEMBL31180565 | 0.73 | BRD4 (0.37) | BRD4BRD9BRD7BRD2L3MBTL1 | |
| SCHEMBL25469043 | 0.73 | KDM4E (0.42) | ALDH1A1LMNA | |
| SCHEMBL18644923 | 0.72 | FAAH (0.33) | BRD4BRD9BRD7BRD2LMNA | |
| SCHEMBL29911810 | 0.72 | BRD4 (0.33) | BRD4BRD9BRD7BRD2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4038059-B1 | SUBSTITUTED CARBAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021067657-A1 | SUBSTITUTED CARBAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067326-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | NAGATO SATOSHI | 2009-11-05 | — | — | US | disclosed |
| US-7563811-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | GRIK1, GRIK2, GRIK5 | BRD4 757/4885BRD9 842/4885BRD7 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.